Actelion (ALIOY.PK), Europe's biggest biotech company, posts encouraging results from a mid-stage clinical trial of ponesimod, a treatment for skin disease psoriasis, with 46% of patients suffering from moderate to severe chronic plaque psoriasis seeing a 75% improvement in an index for monitoring the disease at 16 weeks when treated with a 20 milligram dose.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs